Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by glecaprevir and pibrentasvir therapy in HCV-infected hemodialysis patients
Latest Information Update: 26 Aug 2022
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- 25 Aug 2022 Status changed from active, no longer recruiting to completed.
- 05 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Jan 2018 New trial record